Testosterone is unquestionably a normal female hormone that exerts important physiological effects in multiple tissues. Clinical trials have consistently demonstrated benefits of testosterone therapy on several domains of sexual function for postmenopausal women with low sexual desire causing substantial personal concern. Whether other benefits can be attributed to testosterone therapy for postmenopausal women remains uncertain. This article summarizes the available data for the use of testosterone therapy beyond the treatment of low sexual desire with distress. The article is not a systematic review of the entire published literature in the field. Rather, it includes recent systematic reviews and meta-analyses the author highlighted in their plenary lecture at the 2024 World Congress on the Menopause. The aim was to provide an overview of the published data for clinicians and researchers in this field.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13697137.2024.2445301 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies.
J Vis Exp
January 2025
Center for Gender-Specific Medicine, Istituto Superiore di Sanità.
Transgender (TG) people are individuals whose gender identity and sex assigned at birth do not match. They often undergo gender-affirming hormone therapy (GAHT), a medical intervention that allows the acquisition of secondary sex characteristics more aligned with their individual gender identity, providing consistent results in the improvement of numerous socio-psychological variables. However, GAHT targets different body systems, and some side effects are recorded, although not yet fully identified and characterized.
View Article and Find Full Text PDFThe Impact of Levothyroxine and Testosterone Administration on Bladder Contractility in the Rat Model of Propylthiouracil-Induced Hypothyroidism.
Urol Res Pract
January 2025
Department of Pharmacology, Ankara University, Faculty of Pharmacy, Ankara, Türkiye.
Objective: To investigate the effects of testosterone (T) treatment, with or without levothyroxine, the most widely used and least effective medication for managing hypothyroidism, on the functional and histological changes in propylthiouracil (PTU)- induced hypothyroid rat bladders.
Methods: Male rats (n=35) were split into control, hypothyroid, hypothyroid rats treated with levothyroxine (20 µg/kg/day, oral, 2-weeks), hypothyroid rats treated with Sustanon (10 mg/kg,iIM, once/week, 2-weeks), and hypothyroid rats treated with combined treatment groups. Hypothyroidism was induced by PTU (0.
Lycopene Ameliorates Polycystic Ovary Syndrome in Rats by Inhibiting Ovarian Ferroptosis Through Activation of the AMPK/Nrf2 Pathway.
J Biochem Mol Toxicol
February 2025
Department of Gynecology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Lycopene (LYC) is an extremely powerful antioxidant with the potential to treat a range of diseases and to inhibit ferroptosis. This research aims to elucidate how LYC impacts polycystic ovarian syndrome (PCOS) and the action mechanisms. A PCOS rat model was constructed by injecting DHEA.
View Article and Find Full Text PDFFormononetin ameliorates polycystic ovary syndrome through suppressing NLRP3 inflammasome.
Mol Med
January 2025
Reproduction and Genetics Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, 42 Wenhua West Road, Lixia District, Jinan, 250014, Shandong, China.
Background: Polycystic ovary syndrome (PCOS) is a common gynecological disease accompanied by multiple clinical features, including anovulation, hyperandrogenism, and polycystic ovarian morphology, leading to infertility. Formononetin (FMN), which is a major bioactive isoflavone compound in Astragalus membranaceus, exerts anti-inflammatory effects. However, whether FMN is effective in the treatment of PCOS remains unknown.
View Article and Find Full Text PDFTestosterone-induced Seminal Vesicle-like Differentiation in Cervical Mesonephric Duct Remnants in a Female to Male Transgender Patient.
Int J Gynecol Pathol
January 2025
Department of Pathology, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK.
Pure ductal-type mesonephric remnants in the uterine cervix are rare. We report an unusual case in a 31-yr-old of cervical mesonephric remnants of predominantly ductal type exhibiting seminal vesicle-like differentiation in a female-to-male transgender patient receiving long-term testosterone therapy. To the best of our knowledge, this phenomenon has not been previously reported.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!